Executive Profile

Bruce R. Zetter Ph.D. Co-Founder and Chairman of the Scientific Advisory Board, Predictive Biosciences, Inc.

Age	Total Calculated Compensation	This person is connected to 7 Board Members in 7 different organizations across 8 different industries. See Board Relationships
--	--

Background

Dr. Bruce R. Zetter, Ph.D. co-founded Predictive Biosciences Inc. in 2006. Dr. Zetter serves as Chief Scientific Officer and Vice President of Research at Boston Children's Hospital and the Charles Nowiszewski Professor of Cancer Biology at Harvard Medical School. Dr. Zetter serves as a Professor in the Department of Surgery at Harvard Medical School. He also serves as a consultant and scientific advisor to major biotechnology and pharmaceutical companies. Dr. Zetter ... is highly regarded nationally and internationally as a leader in the research of tumor angiogenesis, progression, cancer diagnosis, and cancer metastasis. He serves as Member of Scientific & Medical Advisory Board of ProNAi Therapeutics, Inc and served as its Head of Scientific Advisors since November 2012. He serves as a Medical & Scientific Advisor of Mersana Therapeutics Inc. Dr. Zetter served as an expert witness for the United States Senate Cancer Coalition hearings in Washington, DC. He serves as Chairman of Scientific Advisory Board of the Scientific Advisory Board of SynDevRx, Inc., and Cerulean Pharma Inc. He serves as Chairman of Scientific Advisory Board of Tempo Pharmaceuticals Inc. and Predictive Biosciences, Inc. Dr. Zetter serves as a Member of the Board of Directors and Member of Advisory Board of Attenuon, LLC. Dr. Zetter serves on the Advisory Boards of Angstrom Pharmaceuticals and GMP Companies. He also serves on several grant review boards for public agencies such as the American Heart Association and American Cancer Society, and serves on the editorial board of eight peer- reviewed journals. Dr. Zetter served as Member of Scientific Advisory Board of Tempo Pharmaceuticals Inc., Synta Pharmaceuticals Corp., and BioTrove, Inc. His research interests focus on tumor metastasis and on identifying diagnostic and prognostic markers that can guide treatment decisions. He has chaired the grant review board on breast and prostate cancer for the National Institutes of Health. Dr. Zetter is a pioneer in understanding how cell movement affects tumor etastasis and is recognized for his key discovery of the inhibitory effects of alpha interferon to endothelial cell locomotion. His work led to the use of interferon alpha to treat hemangiomas. Dr. Zetter has won numerous national and international awards for his work in the field of cancer research including a Faculty Research Award from the American Cancer Society and the prestigious MERIT award from the US National Cancer Institute. He has authored more than 100 articles and has more than 20 patents to his credit. Dr. Zetter earned his Ph.D. from University of Rhode Island and he completed postdoctoral fellowships at Massachusetts Institute of Technology (MIT) and the Salk Institute in San Diego.

Corporate Headquarters 128 Spring Street Lexington, Massachusetts 02421 United States Phone: 781-402-1780 Fax: 781-402-1785 Board Members Memberships There is no Board Members Memberships data available. Education PhD University Of Rhode Island Other Affiliations Mersana Therapeutics, Inc. Attenuon, LLC BioTrove, Inc. Synta Pharmaceuticals Corp. University Of Rhode Island ProNAi Therapeutics, Inc. Cerulean Pharma Inc. SynDevRx, Inc.

Annual Compensation There is no Annual Compensation data available. Stocks Options There is no Stock Options data available. Total Compensation There is no Total Compensation data available.

COMPETITOR COMPENSATION

There is no Competitor Compensation data available.